Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Innovent Biologics

Status and phase

Enrolling

Phase 3

Conditions

Primary Peritoneal

Fallopian Tube Cancer

Ovarian

Treatments

Drug: paclitaxel/Gemcitabine/Liposomal doxorubicin

Drug: IBI354

Study type

Interventional

Funder types

Industry

Identifiers

NCT06834672

CIBI354A301

Details and patient eligibility

About

This is a multiregional, multicenter, randomized, open-label, phase III study to compare the efficacy, safety, and tolerability of IBI354 monotherapy with investigator's choice of chemotherapy (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan) in patients with HER2-expressing, platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer.

Participants with advanced ovarian, primary peritoneal, fallopian tube cancer who have failed or are intolerant to first-line or more platinum-based chemotherapy will be randomly assigned in a 2:1 ratio to two treatment arms:

Experimental Arm: IBI354 monotherapy arm, 12 mg/kg IBI354 on Day 1 of each 3-week cycle; Control Arm: Investigator's choice chemotherapy (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan)

Enrollment

450 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Participants have the ability to understand and give written informed consent Form (ICF) for participation in this trial, including all evaluations and procedures as specified by this protocol;
Female participants ≥ 18 years old;
Expected life time ≥ 12 weeks
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
Histologically or cytologically confirmed locally advanced unresectable or metastatic ovarian, primary peritoneal, or fallopian tube cancer.
Must have confirmed disease progression during or after the most recent anticancer therapy.
Must have at least 1 measurable target lesion per RECIST v1.1 criteria.
Left Ventricular Ejection Fraction (LVEF) ≥ 50% within 28 days prior to the first dose of study drug.
Adequate bone marrow and organ function.
Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study drug and use effective contraception throughout the treatment period and for 6 months after the treatment period.

Exclusion Criteria:

Patients with histological or cytological findings meet any of the following criteria:
1. Endometrioid tumor, clear cell tumor, mucinous tumor, mesenchymal tumor, or contains any of the above components.
2. Low-grade or borderline tumor, or contains any of the above components.
Participation in any other interventional clinical study, except observational (non-interventional) study.
Paclitaxel, gemcitabine, liposomal doxorubicin, and topotecan listed in the control arm were either ineligible or had previously received and progressed.
Prior therapy to first dose of study drug:
1. Participants who have been treated with Intravenous infusion of chemotherapeutic drugs, macromolecular targeted drugs, immunotherapy, intraperitoneal chemotherapy, tumor embolization or interventional chemotherapy, within 4 weeks.
2. Participants who have been treated with oral chemotherapeutic drugs, small molecular targeted drugs, endocrine therapy, and Chinese herbal medicine for anticancer treatment indications, within 2 weeks or 5 half-lives (whichever is longer).
3. Participants who have been treated with radical radiotherapy within 4 weeks, palliative radiotherapy within 2 weeks.
4. Participants who have been treated with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 2 weeks or 5 half-lives (whichever is longer).
5. Participants who have been treated with Major surgery (craniotomy, thoracotomy or laparotomy and other types of surgery considered "major" by the investigator, excluding needle biopsy) within 4 weeks; Laparoscopic exploration surgery within 2 weeks. Or participants have serious non-healing wound, trauma or ulcer.
6. Participants who have been treated with live vaccines (mRNA and non-replicating adenovirus vaccines are not considered live vaccines) within 4 weeks.
Have adverse reactions caused by previous anti-tumor therapy that have not been resolved to Grade 0 or 1 according to NCI-CTCAE v5.0 criteria.
Presence of symptomatic central nervous system (CNS) metastases, spinal cord compression, carcinomatous meningitis, or history of leptomeningeal carcinoma.
Participants with pneumonitis requiring corticosteroid treatment, or a history of other clinically significant lung disease.
Uncontrolled or significant cardiovascular and cerebrovascular disease.
Use of immunosuppressive medications within 14 days prior to the first dose of study treatment.
Tumor invades surrounding important tissues or organs.
Bleeding within 3 months prior to the first dose of study treatment.
Symptomatic abdominal or pelvic effusion requiring intervention.
Esophageal or gastric varices that require immediate intervention (e.g., ligation or sclerotherapy), or have high risk of bleeding considered by the investigator or gastroenterology and hepatology specialists; participants with evidence of portal hypertension.
Unhealed gastrointestinal obstruction, perforation, or fistula, or participants at risk for gastrointestinal obstruction or perforation.
Have intraluminal stenting of the digestive tract or trachea.
Participants with biliary obstruction will be excluded.
Participants with hepatic encephalopathy, hepatorenal syndrome, or cirrhosis of Child-Pugh class B or above.
Significant malnutrition.
Uncontrolled active infection.
Concomitant other primary malignancies within 3 years or other malignancies with active or risk of recurrence before the first dose of study treatment.
History of immunodeficiency disease, including congenital or acquired immunodeficiency disease.
History of allogeneic organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.
Allergy to other anti-HER2 antibodies/ADC or any component of IBI354.
Participants who are pregnant or lactating, or those who plan to become pregnant.
Other acute or chronic diseases or laboratory abnormalities that may increase the risk of participation in the study or administration of the study treatment, interfere with the interpretation of the study results, or lead the investigator to determine that the participant is inappropriate for participation in the study.
The participant has neurological, psychiatric, or social conditions that affect trial compliance, significantly increase the risk of adverse events, or affect the participant's ability to provide written informed consent.